Liver cancer study tests best antiviral combo for immunotherapy patients
NCT ID NCT07253220
First seen Jan 04, 2026 · Last updated Apr 28, 2026 · Updated 17 times
Summary
This study looks at 120 people with advanced liver cancer caused by hepatitis B who are also getting immunotherapy. It compares two antiviral drug plans: one using TAF alone, and the other using TAF plus ETV. The goal is to see which plan helps people live longer and better controls the hepatitis B virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.